---
title: "Neoehrlichia mikurensis Infection Causing Recurrent Fever in an Immunocompromised Patient, Netherl"
id: "cdc-emerging-infectious-diseases-journal-2-neoehrlichia-mikurensis-infection-in-immunocompromised-patient-the-netherlands"
canonical_url: "https://medichelpline.com/clinical-feed/cdc-emerging-infectious-diseases-journal-2-neoehrlichia-mikurensis-infection-in-immunocompromised-patient-the-netherlands"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "CDC Emerging Infectious Diseases Journal"
source_url: "https://wwwnc.cdc.gov/eid/article/32/12/26-1316_article"
published_at: "2026-11-02T05:00:00.000Z"
evidence_level: "Agency Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Neoehrlichia mikurensis Infection Causing Recurrent Fever in an Immunocompromised Patient, Netherl
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/cdc-emerging-infectious-diseases-journal-2-neoehrlichia-mikurensis-infection-in-immunocompromised-patient-the-netherlands
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** CDC Emerging Infectious Diseases Journal
- **Source URL:** [Original Journal Publication](https://wwwnc.cdc.gov/eid/article/32/12/26-1316_article)
- **Published At:** 2026-11-02T05:00:00.000Z
- **Evidence Rating:** Agency Feed
## Executive GIST (TL;DR)
- Case report of a 69-year-old man with indolent non-Hodgkin lymphoma who developed recurrent, cyclical fevers after starting immunochemotherapy (R-CVP) in April 2024. - Symptoms included high fevers (up to 41.1°C), chills, night sweats, bilateral leg edema, hypotension, and tachycardia during inflammatory episodes. - Initial workup (chest radiograph, urine analysis, blood cultures) was negative; laboratory results showed leukocytosis and elevated C-reactive protein. - Empirical cefuroxime was given twice with no clinical or microbiologic response; nonsteroidal antiinflammatory drugs temporarily reduced fever. - Broad-range 16S V3–V4 PCR and sequencing identified **Neoehrlichia mikurensis** DNA; species-specific PCR at the national reference lab confirmed diagnosis. - Treatment with **doxycycline** 100 mg twice daily for 3 weeks was started on January 7, 2025; fever and edema resolved within days and follow-up PCRs at 3 and 6 months were negative. - The patient had no reported tick bite but had recent hiking exposure in a national park; the study notes increasing detection of **N. mikurensis** in Europe and high prevalence in **Ixodes ricinus** ticks. - Detection relies on targeted PCR or broad-range 16S rRNA sequencing available only in equipped laboratories. - The authors observed that infections are more frequent and clinically apparent in patients receiving B-cell–depleting therapies such as **rituximab**. - The report calls for prospective studies of patients with fever after tick exposure to better define incidence, diagnostics, and optimal treatment duration in immunocompromised populations.
## Clinical Analysis & Structured Key Points
[Skip directly to page options](https://wwwnc.cdc.gov/eid/article/32/12/26-1316_article#share-nav) [Skip directly to A-Z link](https://wwwnc.cdc.gov/eid/article/32/12/26-1316_article#az-large) ![](https://wwwnc.cdc.gov/TemplatePackage/4.0/assets/imgs/uswds/us_flag_small.png) An official website of the United States government Here's how you know ![](https://wwwnc.cdc.gov/TemplatePackage/4.0/assets/imgs/uswds/icon-dot-gov.svg) **Official websites use .gov** A .gov website belongs to an official government organization in the United States. ![](https://wwwnc.cdc.gov/TemplatePackage/4.0/assets/imgs/uswds/icon-https.svg) **Secure .gov websites use HTTPS** A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites. [CDC Home](https://wwwnc.cdc.gov/) [ ![Centers for Disease Control and Prevention](https://wwwnc.cdc.gov/TemplatePackage/5.0/img/logo/cdc-logo-tag-right.svg) ](https://www.cdc.gov/) Emerging Infectious Diseases ![](https://wwwnc.cdc.gov/eid/article/32/12/26-1316_article) [A-Z Index](https://www.cdc.gov/az/) × Submit [A-Z Index](https://www.cdc.gov/az/) × Submit [A-Z Index](https://www.cdc.gov/az/) Search Dropdown × Submit Emerging Infectious Diseases * [About the Journal](https://wwwnc.cdc.gov/eid/about) * [ BACK ](https://wwwnc.cdc.gov/eid/article/32/12/26-1316_article) **About the Journal** * [General Information](https://wwwnc.cdc.gov/eid/about/general) * [ BACK ](https://wwwnc.cdc.gov/eid/article/32/12/26-1316_article) **General Information** * [ BACK ](https://wwwnc.cdc.gov/eid/article/32/12/26-1316_article) **About the Journal****General Information** * [Background and Goals](https://wwwnc.cdc.gov/eid/about/background) * [Editors](https://wwwnc.cdc.gov/eid/about/editors) * [Editorial Board](https://wwwnc.cdc.gov/eid/about/editorial-board) * [Staff](https://wwwnc.cdc.gov/eid/about/staff) * [ Home](https://wwwnc.cdc.gov/) * [Contact](https://wwwnc.cdc.gov/eid/contact) * [EID Journal Report 2025](https://wwwnc.cdc.gov/eid/pdfs/JournalReport_2025.pdf) * [ Home](https://wwwnc.cdc.gov/) * [Articles](https://wwwnc.cdc.gov/eid/) * [ BACK ](https://wwwnc.cdc.gov/eid/article/32/12/26-1316_article) **Articles** * [November 2026](https://wwwnc.cdc.gov/eid/current) * [Wastewater Surveillance](https://wwwnc.cdc.gov/eid/articles/issue/32/13/table-of-contents) * [Early Release](https://wwwnc.cdc.gov/eid/early-release) * [ BACK ](https://wwwnc.cdc.gov/eid/article/32/12/26-1316_article) **Early Release** * [ BACK ](https://wwwnc.cdc.gov/eid/article/32/12/26-1316_article) **Articles****Early Release** * [Neoehrlichia mikurensis Infection in Immunocompromised Patient, the Netherlands, 2024](https://wwwnc.cdc.gov/eid/article/32/12/26-1316_article) * [ BACK ](https://wwwnc.cdc.gov/eid/article/32/12/26-1316_article) **Neoehrlichia mikurensis Infection in Immunocompromised Patient, the Netherlands, 2024** * [ BACK ](https://wwwnc.cdc.gov/eid/article/32/12/26-1316_article) **Early Release****Neoehrlichia mikurensis Infection in Immunocompromised Patient, the Netherlands, 2024** * [ BACK ](https://wwwnc.cdc.gov/eid/article/32/12/26-1316_article) **Articles****Early Release****Neoehrlichia mikurensis Infection in Immunocompromised Patient, the Netherlands, 2024** * [Figure](https://wwwnc.cdc.gov/eid/article/32/12/26-1316-f1) * [ Home](https://wwwnc.cdc.gov/) * [ Home](https://wwwnc.cdc.gov/) * [Past Issues](https://wwwnc.cdc.gov/eid/past-issues/volume-32) * [Medscape CME](https://wwwnc.cdc.gov/eid/articles/cme) * [ICEID](https://wwwnc.cdc.gov/eid/page/iceid) * [ Home](https://wwwnc.cdc.gov/) * [Search](https://wwwnc.cdc.gov/eid/Search) * [ BACK ](https://wwwnc.cdc.gov/eid/article/32/12/26-1316_article) **Search** * [Advanced Article Search](https://wwwnc.cdc.gov/eid/AdvancedSearch) * [Articles by Country Search](https://wwwnc.cdc.gov/eid/ArticleMap) * [Spotlight Topics](https://wwwnc.cdc.gov/eid/spotlight) * [ BACK ](https://wwwnc.cdc.gov/eid/article/32/12/26-1316_article) **Spotlight Topics** * [ BACK ](https://wwwnc.cdc.gov/eid/article/32/12/26-1316_article) **Search****Spotlight Topics** * [Antimicrobial Resistance Spotlight](https://wwwnc.cdc.gov/eid/spotlight/antimicrobial-resistance) * [Coronavirus Spotlight](https://wwwnc.cdc.gov/eid/spotlight/coronavirus) * [Ebola Spotlight](https://wwwnc.cdc.gov/eid/spotlight/ebola) * [Etymologia](https://wwwnc.cdc.gov/eid/articles/etymologia) * [Foodborne Diseases and Outbreaks Spotlight](https://wwwnc.cdc.gov/eid/spotlight/foodborne-diseases) * [Fungal Diseases](https://wwwnc.cdc.gov/eid/spotlight/fungal) * [Hantavirus Spotlight](https://wwwnc.cdc.gov/eid/spotlight/hantavirus) * [HIV/AIDS Spotlight](https://wwwnc.cdc.gov/eid/spotlight/hiv) * [Influenza Spotlight](https://wwwnc.cdc.gov/eid/spotlight/influenza) * [Lyme Disease Spotlight](https://wwwnc.cdc.gov/eid/spotlight/lyme-disease) * [Malaria Spotlight](https://wwwnc.cdc.gov/eid/spotlight/malaria) * [MERS Spotlight](https://wwwnc.cdc.gov/eid/spotlight/mers) * [Mpox Spotlight](https://wwwnc.cdc.gov/eid/spotlight/mpox) * [Pneumonia Spotlight](https://wwwnc.cdc.gov/eid/spotlight/pneumonia) * [Rabies Spotlight](https://wwwnc.cdc.gov/eid/spotlight/rabies) * [Ticks Spotlight](https://wwwnc.cdc.gov/eid/spotlight/ticks) * [Tuberculosis/Mycobacteria](https://wwwnc.cdc.gov/eid/spotlight/tuberculosis) * [Zika Spotlight](https://wwwnc.cdc.gov/eid/spotlight/zika) * [ Home](https://wwwnc.cdc.gov/) * [Article Type Search](https://wwwnc.cdc.gov/eid/ArticleTypeSearch) * [EID on PubMed Central](https://www.ncbi.nlm.nih.gov/pmc/journals/782/) * [ Home](https://wwwnc.cdc.gov/) * [Subscribe](https://wwwnc.cdc.gov/eid/subscriptions) * [Author Resource Center](https://wwwnc.cdc.gov/eid/page/author-resource-center) * [Peer Reviewers](https://wwwnc.cdc.gov/eid/reviewers) * [Podcasts](https://wwwnc.cdc.gov/eid/podcasts) * [ BACK ](https://wwwnc.cdc.gov/eid/article/32/12/26-1316_article) **Podcasts** * [Search](https://wwwnc.cdc.gov/eid/podcasts/search) * [ Home](https://wwwnc.cdc.gov/) * [Social Media](https://wwwnc.cdc.gov/eid/page/social-media) * [ Press & Media Information](https://wwwnc.cdc.gov/eid/press) * [ Home](https://wwwnc.cdc.gov/) 1. [EID Journal](https://wwwnc.cdc.gov/eid/) 2. [Volume 32](https://wwwnc.cdc.gov/eid/early-release) 3. [Early Release](https://wwwnc.cdc.gov/eid/early-release#issue-1348) 4. [Main Article](https://wwwnc.cdc.gov/eid/article/32/12/26-1316_article) * [Facebook](https://www.facebook.com/sharer/sharer.php?u=%2Feid%2Farticle%2F32%2F12%2F26-1316_article "Share to Facebook") * [Twitter](http://twitter.com/share?url=%2Feid%2Farticle%2F32%2F12%2F26-1316_article&text= "Share to Twitter") * [LinkedIn](https://www.linkedin.com/shareArticle?url=%2Feid%2Farticle%2F32%2F12%2F26-1316_article&title= "Share to LinkedIn") * [Syndicate](https://tools.cdc.gov/medialibrary/index.aspx#/sharecontent//eid/article/32/12/26-1316_article "Embed this Page") [ Emerging Infectious Disease journal ISSN: 1080-6059 ](https://wwwnc.cdc.gov/eid/) _Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released._ #### Volume 32, Number 12—December 2026 ##### _Research Letter_ ### _Neoehrlichia mikurensis_ Infection in Immunocompromised Patient, the Netherlands, 2024 On This Page [Research Letter](https://wwwnc.cdc.gov/eid/article/32/12/26-1316_article) * * * [Suggested Citation](https://wwwnc.cdc.gov/eid/article/32/12/26-1316_article) Figures [Figure](https://wwwnc.cdc.gov/eid/article/32/12/26-1316-f1) Downloads [RIS [TXT - 2 KB] ](https://wwwnc.cdc.gov/eid/article/32/12/26-1316.ris) Article Metrics [Metric Details](https://wwwnc.cdc.gov/eid/article/32/12/26-1316_article) Related Articles [Wild Mice and Shrews as Reservoirs of Yezo Virus](https://wwwnc.cdc.gov/eid/article/32/12/26-0298_article) * * * [Fatal Rickettsiosis in Pediatric Patient](https://wwwnc.cdc.gov/eid/article/32/11/26-1174_article) * * * [_Anaplasma capra_ , Turkey, 2022](https://wwwnc.cdc.gov/eid/article/32/10/25-1049_article) * * * [More articles on Ticks](https://wwwnc.cdc.gov/eid/spotlight/ticks) Martijn J.H. Tjan[1](https://wwwnc.cdc.gov/eid/article/32/12/26-1316_article#fn1)[2](https://wwwnc.cdc.gov/eid/article/32/12/26-1316_article#fn2), William J. Boogers[1](https://wwwnc.cdc.gov/eid/article/32/12/26-1316_article#fn1)[![Comments to Author](https://wwwnc.cdc.gov/eid/content/images/icon/email.gif)](https://wwwnc.cdc.gov/eid/article/32/12/26-1316_article#comment) , Jaco J. Verweij, Marvin A.H. Berrevoets, and Joppe W. Hovius Author affiliation: Elisabeth-TweeSteden Hospital, Tilburg, the Netherlands (M.J.H. Tjan, W.J. Boogers, J.J. Verweij, M.A.H. Berrevoets); Amsterdam University Medical Center, Amsterdam, the Netherlands (J.W. Hovius) [Suggested citation for this article](https://wwwnc.cdc.gov/eid/article/32/12/26-1316_article#suggestedcitation) ### Abstract We report a case of _Neoehrlichia mikurensis_ infection from a tick bite in a 69-year-old immunocompromised man with non-Hodgkin lymphoma in the Netherlands. Because of increasing use of immunosuppressive therapies and frequent tick bites, _N. mikurensis_ should be recognized as a potential cause of recurrent fever in immunocompromised patients. _Neoehrlichia mikurensis_ is a gram-negative tickborne bacterium increasingly identified in Europe and Asia ([_1_](https://wwwnc.cdc.gov/eid/article/32/12/26-1316_article#r1 "1")). Clinical manifestations of infection are fever, chills, night sweats, and systemic inflammatory responses, particularly in immunocompromised patients. We describe the case of _N. mikurensis_ infection in a man who had recurrent, cyclical fever over a 1-year period. A 69-year-old man with indolent non-Hodgkin lymphoma was undergoing immunochemotherapy consisting of rituximab, a CD20 monoclonal antibody that depletes B lymphocytes, along with cyclophosphamide, vincristine, and prednisolone (R-CVP regimen); treatment began in April 2024. He was admitted to Elisabeth-TweeSteden Hospital, Tilburg, the Netherland, on July 23, 2024, with nonneutropenic fever, chills, night sweats, and mild bilateral edema of the legs. Apart from hiking in a national park in the Netherlands, he reported no other risk factors for infectious diseases (e.g., tick bite, travel abroad). Standard investigations, including chest radiograph, urine analysis, and blood cultures, were unremarkable. However, laboratory results showed the presence of leukocytosis (10.1 × 109 cells/L; reference range 4.0–10.0 × 109 cells/L) and a C-reactive protein level of 124 mg/L (reference 5 days, prompting a positron emission tomography scan, which showed no infectious or inflammatory foci but did show good response to his lymphoma treatment. The patient felt unwell during fever episodes but was symptom free between those episodes ([Figure](https://wwwnc.cdc.gov/eid/article/32/12/26-1316-f1)). We discontinued cefuroxime and discharged him after 10 days. After discharge, night sweats and edema began subsiding, and the patient had mostly recovered. However, during the last 2 therapy cycles for his lymphoma, night sweats returned, along with edema, chills, and fever. During follow-up on November 19, he was readmitted with a fever (40.3°C) and treated again with cefuroxime. We found no cause for the edema; echocardiography and chest radiograph showed no signs of right heart failure. Further diagnostic tests, including those for serum albumin and urine protein levels, were unremarkable. During hospital stays, each episode of chills and fever led to intercurrent systemic inflammatory response syndrome accompanied by severe hypotension and tachycardia, necessitating fluid resuscitation ([Figure](https://wwwnc.cdc.gov/eid/article/32/12/26-1316-f1)). We discontinued cefuroxime because of the absence of clinical response and negative blood cultures. After starting nonsteroidal antiinflammatory drugs on November 25, which seemed to reduce the fever, we discharged the patient on November 28. On December 31, the patient was readmitted with similar symptoms. On January 2, 2025, a bone marrow biopsy was performed, which appeared to be reactive and did not show signs of lymphoma or other malignancies. The episodes of fever persisted with a noticeable cyclical pattern of ≈48 hours ([Figure](https://wwwnc.cdc.gov/eid/article/32/12/26-1316-f1)). Each episode began with chills, followed by fever up to 41.1°C and systemic inflammatory response syndrome reactions. Ultimately, broad-range PCR that targeted the 16S V3–V4 region of bacterial rRNA followed by sequencing revealed the presence of _N. mikurensis_ DNA. An _N. mikurensis_ –specific PCR of blood, performed at the National Institute for Public Health and the Environment in the Netherlands, confirmed the diagnosis. The patient started treatment with doxycycline on January 7 for 3 weeks, after which the fever and edema subsided within days. PCR of blood samples collected 3 and 6 months after doxycycline treatment were negative for _N. mikurensis_. _N. mikurensis_ is an emerging intracellular bacterium transmitted by ticks and is increasingly recognized as a major pathogen in immunocompromised populations. In a cohort study from Sweden, a substantial percentage of patients with _N. mikurensis_ infections were undergoing immunosuppressive therapies that included rituximab and other B-cell–depleting agents ([_1_](https://wwwnc.cdc.gov/eid/article/32/12/26-1316_article#r1 "1")). The epidemiology of _N. mikurensis_ indicates that infections primarily occur in areas where ticks, particularly _Ixodes ricinus_ ticks, are endemic. In western Europe, _N. mikurensis_ has been detected in up to 24.2% of _I_. _ricinus_ ticks ([_2_](https://wwwnc.cdc.gov/eid/article/32/12/26-1316_article#r2 "2")). Clinical symptoms of _N. mikurensis_ infection are diverse, ranging from mild fever and general malaise to more severe manifestations, such as vasculitis and thromboembolic events. Recognizing clinical manifestations of _N. mikurensis_ is crucial, particularly because symptoms often do not align with typical infectious conditions and can lead to underdiagnosis ([_3_](https://wwwnc.cdc.gov/eid/article/32/12/26-1316_article#r3 "3")). Moreover, incidence of clinically relevant _N. mikurensis_ infections is likely to increase as use of immunosuppressive therapies rises ([_4_](https://wwwnc.cdc.gov/eid/article/32/12/26-1316_article#r4 "4")). Detection of _N. mikurensis_ is diagnostically challenging. Current methods are limited to PCR that specifically tests for _N. mikurensis_ or broadly tests for 16S rRNA; those methods are restricted to laboratories with appropriate resources ([_5_](https://wwwnc.cdc.gov/eid/article/32/12/26-1316_article#r5 "5")). The recommended treatment for _N. mikurensis_ infection is oral doxycycline at a dose of 100 mg 2×/day for 2–3 weeks, which has been shown to effectively eradicate the infection and lead to a rapid resolution of symptoms in patients. Shorter courses or lower doses of doxycycline might result in recurrence of infection, particularly in immunocompromised persons ([_3_](https://wwwnc.cdc.gov/eid/article/32/12/26-1316_article#r3 "3"),[_6_](https://wwwnc.cdc.gov/eid/article/32/12/26-1316_article#r6 "6")). In conclusion, clinically relevant _N. mikurensis_ infections in the Netherlands might increase because of the growing use of immunosuppressive therapies and frequent human _I. ricinus_ tick bites. Further studies are needed, such as prospective studies of patients with fever after a tick bite ([_7_](https://wwwnc.cdc.gov/eid/article/32/12/26-1316_article#r7 "7")). _N. mikurensis_ should be recognized as a potential cause of recurrent fever in immunocompromised patients. Mr. Tjan was a resident in the Internal Medicine Department at the Elisabeth-TweeSteden Hospital during the treatment of the patient described in this case report. His interests focus on pathogenesis of diseases, particularly those in medical oncology. [TopExternal Link](javascript:void\(0\)) ### References 1. Wennerås C. Infections with the tick-borne bacterium _Candidatus_ Neoehrlichia mikurensis. Clin Microbiol Infect. 2015;21:621–30 .[DOIExternal Link](https://doi.org/10.1016/j.cmi.2015.02.030 "DOI")[PubMedExternal Link](https://pubmed.ncbi.nlm.nih.gov/25770773 "PubMed")[Google ScholarExternal Link](https://scholar.google.com/scholar_lookup?doi=10.1016%2fj.cmi.2015.02.030&pmid=25770773 "Google Scholar") 2. Portillo A, Santibáñez P, Palomar AM, Santibáñez S, Oteo JA. ‘ _Candidatus_ Neoehrlichia mikurensis’ in Europe. New Microbes New Infect. 2018;22:30–6 .[DOIExternal Link](https://doi.org/10.1016/j.nmni.2017.12.011 "DOI")[PubMedExternal Link](https://pubmed.ncbi.nlm.nih.gov/29556406 "PubMed")[Google ScholarExternal Link](https://scholar.google.com/scholar_lookup?doi=10.1016%2fj.nmni.2017.12.011&pmid=29556406 "Google Scholar") 3. Wennerås C, Wass L, Bergström B, Grankvist A, Lingblom C. Ten years of detecting _Neoehrlichia mikurensis_ infections in Sweden: demographic, clinical and inflammatory parameters. Eur J Clin Microbiol Infect Dis. 2024;43:2083–92 .[DOIExternal Link](https://doi.org/10.1007/s10096-024-04909-5 "DOI")[PubMedExternal Link](https://pubmed.ncbi.nlm.nih.gov/39136831 "PubMed")[Google ScholarExternal Link](https://scholar.google.com/scholar_lookup?doi=10.1007%2fs10096-024-04909-5&pmid=39136831 "Google Scholar") 4. Martinson ML, Lapham J. Prevalence of immunosuppression among US adults. JAMA. 2024;331:880–2 .[DOIExternal Link](https://doi.org/10.1001/jama.2023.28019 "DOI")[PubMedExternal Link](https://pubmed.ncbi.nlm.nih.gov/38358771 "PubMed")[Google ScholarExternal Link](https://scholar.google.com/scholar_lookup?doi=10.1001%2fjama.2023.28019&pmid=38358771 "Google Scholar") 5. Eikeland R, Henningsson AJ, Lebech AM, Kerlefsen Y, Mavin S, Vrijlandt A, et al. Tick-borne diseases in the North Sea region—a comprehensive overview and recommendations for diagnostics and treatment. Ticks Tick Borne Dis. 2024;15:102306 .[DOIExternal Link](https://doi.org/10.1016/j.ttbdis.2023.102306 "DOI")[PubMedExternal Link](https://pubmed.ncbi.nlm.nih.gov/38183851 "PubMed")[Google ScholarExternal Link](https://scholar.google.com/scholar_lookup?doi=10.1016%2fj.ttbdis.2023.102306&pmid=38183851 "Google Scholar") 6. Mens H, Gynthersen R, Christensen JR, Blinkenberg M, Sellebjerg F, El Fassi D, et al. Prevalence of tick-borne _Neoehrlichia mikurensis_ in individuals undergoing B-cell depleting therapy in Denmark: a prospective cohort study 2023–2024. Int J Infect Dis. 2025;161:108069 .[DOIExternal Link](https://doi.org/10.1016/j.ijid.2025.108069 "DOI")[PubMedExternal Link](https:/
## Related Clinical Research

- [Probable CLIPPERS in a Patient with Cutaneous T‑Cell Lymphoma Remission: 5‑Year Follow‑Up (Report](https://medichelpline.com/clinical-feed/frontiers-in-immunology-11-case-report-probable-clippers-in-a-patient-with-cutaneous-t-cell-lymphoma-in.md)
- [Immune-evading universal donor iPSC-derived NK cells: Frontiers in Immunology original research](https://medichelpline.com/clinical-feed/frontiers-in-immunology-13-immune-evading-universal-donor-ipsc-derived-natural-killer-cells-enable-off-the.md)
- [LGsig: Gene-Expression Classifier Integrating Genetics to Predict Therapy Response in DLBCL](https://medichelpline.com/clinical-feed/pubmed-42715516.md) (DOI: 10.1200/JCO-26-00451)
- [Selinexor plus R-CHOP Yields High Response in Newly Diagnosed Double/Triple‑Hit Lymphoma](https://medichelpline.com/clinical-feed/pubmed-42480213.md) (DOI: 10.1182/bloodadvances.2025018580)
- [Pan-B-Lineage Control of Antigen-Heterogeneous Lymphoma Using Adapter CAR-T Cells](https://medichelpline.com/clinical-feed/biorxiv-1-pan-b-lineage-targeting-with-adapter-car-t-cells-controls-antigen-heterogeneous.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.